 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockNews.com lowered shares of MediWound (NASDAQ:MDWD - Free Report) from a hold rating to a sell rating in a research note published on Saturday. Separately, HC Wainwright reiterated a buy rating...

MediWound (NASDAQ:MDWD) Downgraded by StockNews.com

It is a pleasure to report that the MediWound Ltd. ( NASDAQ:MDWD ) is up 40% in the last quarter. Meanwhile over the...

Shareholders in MediWound (NASDAQ:MDWD) have lost 61%, as stock drops 11% this past week

This price move could be a signal that MDWD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

MediWound (MDWD, $14.25) price may climb as it broke lower Bollinger Band on Mar 28, 2024

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mediwound (MDWD Research Report) and Ironwood Pharma...

Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Ironwood Pharma (IRWD)

This is a signal that MDWD's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

MediWound (MDWD, $15.1) Stochastic Oscillator left the oversold zone on March 27, 2024

Silverberg Bernstein Capital Management LLC purchased a new stake in MediWound Ltd. (NASDAQ:MDWD  Free Report) during the fourth quarter, according to its most recent filing with the...

78,984 Shares in MediWound Ltd. (NASDAQ:MDWD) Acquired by Silverberg Bernstein Capital Management LLC

StockNews.com upgraded shares of MediWound (NASDAQ:MDWD  Free Report) from a sell rating to a hold rating in a research note published on Friday.
Separately, HC Wainwright reiterated a buy...

MediWound (NASDAQ:MDWD) Lifted to Hold at StockNews.com

MediWound (NASDAQ:MDWD  Get Free Report)s stock had its buy rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Friday...

MediWound (NASDAQ:MDWD) Earns "Buy" Rating from HC Wainwright

Q4 2023 Mediwound Ltd Earnings Call Transcript

$19 million revenue in 2023; $24 million projected revenue in 2024NexoBrid commercially launched in U.S., Japan, IndiaPotential blockbuster EscharEx to begin Phase III in the second half of 2024$42...

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

Volume (M)	156,507.00
52-Wk High	$18.75
52-Wk Low	$7.10

MDWD MediWound Ltd

About

Feed

News

Earnings

Fundamentals